Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Big Pharma's Pick-Me-Up: A Weak Dollar


Q: What's your opinion of Millennium Pharmaceuticals (MLNM ) and Genentech (DNA )?

DiLorenzo:: For MLNM we have an accumulate ranking, but we consider it speculative because it's a very risky stock. The primary story there is an experimental treatment for cancer called Velcade. Right now, it's being reviewed by the Food & Drug Administration for treatment of multiple myeloma. We think the drug could potentially be approved in the third quarter of 2003, and our rating is predicated on approval and a successful launch. [Note: The FDA approved Velcade on May 14.] However, the company's spend rate on R&D is overly high in our opinion.

Regardin


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus